Released Mar 5, 2025, after the close
10-K filed Mar 5, 2025, 64 days after period end · 0000950170-25-033510
Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.86M$1.86M derived+11.0% vs Q4 2023−39.5% vs Q3 2024
Net Income-$52.15M-$52.15M derivedN/M vs Q4 2023N/M vs Q3 2024
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$61,748,000N/M
Operating Cash Flowderived-$27,799,000N/M
Free Cash Flowderived-$27,897,000N/M
Margins · derived
Operating margin-3319.8%−451.3 pt vs Q4 2023
Net margin-2803.9%−171.3 pt vs Q4 2023
What the release said
The release
Same quarter
| Metric | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures |
|---|---|---|---|---|
| Revenue | $1.86M | $1.68M | $44.36M | $17.07M |
| Net Income | -$52.15M | -$44.12M | -$56.36M | -$68.62M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR